SCHEMBL4019505

SCHEMBL4019505

O=C(O)Nc1ccc(F)cc1-c1ccc(O)c(Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM3 P20309 15/20 0.53
CHRM2 P08172 7/20 0.48
CHRM1 P11229 7/20 0.48
TAS1R3 Q7RTX0 1/20 0.45
TAS1R1 Q7RTX1 1/20 0.45
TAS1R2 Q8TE23 1/20 0.45
ESRRG P62508 1/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
USP2 O75604 1/20 0.43
ALDH1A1 P00352 1/20 0.43
DHFR P00374 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
LMNA P02545 1/20 0.43
TTR P02766 1/20 0.43
ALB P02768 1/20 0.43
HMGB1 P09429 1/20 0.43
HPGD P15428 1/20 0.43
CXCL12 P48061 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16438668 0.89 CHRM3 (0.56) CHRM3CHRM2CHRM1FABP4
SCHEMBL3902040 0.87 CHRM3 (0.61) CHRM3CHRM2CHRM1
SCHEMBL16438690 0.84 CHRM3 (0.52) CHRM3CHRM2CHRM1FABP4
SCHEMBL17797036 0.84 CHRM3 (0.50) CHRM3CHRM2CHRM1FABP4
SCHEMBL17796944 0.82 FABP4 (0.54) CHRM3CHRM2CHRM1TAS1R3TAS1R1
SCHEMBL16438520 0.82 CHRM3 (0.50) CHRM3CHRM2CHRM1FABP4
SCHEMBL4009983 0.81 ESR2 (0.53) KDM4EALDH1A1LMNAHPGDKMT2A
SCHEMBL16438556 0.80 CHRM3 (0.50) CHRM3CHRM2CHRM1MEN1ALDH1A1
SCHEMBL16438674 0.80 CHRM3 (0.54) CHRM3CHRM2CHRM1TAS1R3TAS1R1
SCHEMBL5100285 0.79 CHRM3 (0.56) CHRM3CHRM2CHRM1TAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3029026-B1 NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME DONG A ST CO LTD (KR) 2018-12-05 EP claimed
US-9828339-B2 Biphenyl derivatives and methods for preparing same DONG-A ST CO., LTD (KR) 2017-11-28 US claimed
US-20160176816-A1 NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME DONG-A ST CO., LTD (KR) 2016-06-23 US claimed
EP-3029026-A1 NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME Dong-A ST Co., Ltd. (KR) 2016-06-08 EP claimed
EP-2074094-A1 SULFONAMIDE DERIVATIVES AS ADRENERGIC AGONISTS AND MUSCARINIC ANTAGONISTS Pfizer Limited (GB) 2009-07-01 EP claimed
WO-2008041095-A1 SULFONAMIDE DERIVATIVES AS ADRENERGIC AGONISTS AND MUSCARINIC ANTAGONISTS PFIZER LIMITED (GB) 2008-04-10 WO claimed
EP-3029026-B1 NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME DONG A ST CO LTD (KR) 2018-12-05 EP disclosed
US-9828339-B2 Biphenyl derivatives and methods for preparing same DONG-A ST CO., LTD (KR) 2017-11-28 US disclosed
US-20160176816-A1 NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME DONG-A ST CO., LTD (KR) 2016-06-23 US disclosed
EP-3029026-A1 NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME Dong-A ST Co., Ltd. (KR) 2016-06-08 EP disclosed
EP-2074094-A1 SULFONAMIDE DERIVATIVES AS ADRENERGIC AGONISTS AND MUSCARINIC ANTAGONISTS Pfizer Limited (GB) 2009-07-01 EP disclosed
WO-2008041095-A1 SULFONAMIDE DERIVATIVES AS ADRENERGIC AGONISTS AND MUSCARINIC ANTAGONISTS PFIZER LIMITED (GB) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160176816-A1 NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME CHRM2, CHRM3, CHRM5 CHRM3 2/4885CHRM2 1/4885CHRM1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.